If you are:
FDB Contraindicated or Not Recommended: SALICYLATES NOT RECOMMENDED ESPECIALLY IN 3RD TRIMESTER/NEAR TERM
Only When Necessary: INSUFFICIENT HUMAN & ANIMAL DATA. FDA CATEGORY C IN MULTI-INGREDIENT PRODUCTS
Precaution: INSUFFICIENT DATA AVAIL. MAY POSSIBLY CAUSE SEDATION/ANTIMUSCARINIC EFFECTS.
Absolute Contraindication: ONE REPORT OF METABOL ACIDOSIS W/ASA;RISK OF REYE'S SYN W/VIRAL ILLNESS/FEVER
No Known Risk: LOW LEVELS EXCRETED WITH LOW RISK FOR ADVERSE EFFECTS IN INFANT
An adult over 60:
management or monitoring precaution: General-Elderly have a higher incidence of systemic toxicities. Dose reduction may be needed.
management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating agents preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
management or monitoring precaution: Hepatic-Elderly are more susceptible to hepatotoxicity. Strict adherence to a maximum daily dose of 3000mg is advised.
Giving anabar-capsule to a child under 12:
management or monitoring precaution: Use weight based dosing in children less than 12 years.
Contraindication: Possible CNS excitation and seizure risk in newborns.
Severe Precaution: Do not use in viral illness due to possible increase risk of Reye syndrome.